Dr. Reddy’s entered the North American market in 1986 with exports of the API Methyldopa to the U.S. Over twenty years down the line, we now have a strong commercial presence in North America with in-house sales and marketing teams for both generics (non-branded off-patent formulations) and APIs.Today, Dr. Reddy’s is a major generics player in the North American market with 18 products in over
88 presentations in the U.S., and has also diversified into the OTC (over-the-counter) segment with the September 13, 2007 USFDA approval of our Ranitidine (ZantacTM) 150 mg tablets (OTC).
The 100-member Dr. Reddy’s North America team strives to be the first choice for its customers, leveraging our company’s vertical integration from process development of Active Pharmaceutical Ingredients, Formulations and the submission of ANDAs, through the manufacturing of finished dosages. A group of highly seasoned professionals with a drive to succeed and a rational approach to the market, the North America team is set to take Dr. Reddy’s to the next level and beyond.
Successful track record of market share |
